Astellas' Out-Licensing Deal With Cardeus Could Be Model For Development Outsourcing Of More Of Its Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas has looked to outsource some development programs with "satellite companies" and believes the solution may rest with small startups.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011
Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011
Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.
Deals Of The Week: Cephalon/ChemGenex, Ariad/MolecularMD, RXi/Apthera
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.